Core Insights - Glucotrack, Inc. is set to present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Amsterdam from March 19 to 22, 2025 [1][2] - The CBGM technology allows for real-time glucose monitoring directly from blood, potentially offering greater accuracy without the need for on-body wearables, marking a significant advancement in diabetes management [2][3] Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of innovative technologies for diabetes care, currently developing a long-term implantable continuous blood glucose monitoring system [5][6] - The CBGM is designed to be a long-term implantable device with a sensor longevity of three years, providing continuous and accurate blood glucose monitoring without external components [3][6]
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes